ADHD community seeks DEA action in med shortages

"When you have a controlled substance problem, the DEA has to be involved in fixing it," says Ruth Hughes, CEO at Children and Adults with Attention Deficit/Hyperactivity Disorder. Drugs like Adderall and Ritalin, which have controlled-substance APIs among the 400 basic substances and derivatives regulated by the U.S. Drug Enforcement Agency, present an additional hurdle when it comes to resolving shortages. "It is not sufficient to say it is an industry problem. We need to figure out how to build more flexibility into the system." Story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)